Sue Gail Eckhardt serves as Executive at Syros Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Sue Gail Eckhardt has executed 5 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jun 5, 2024 involved receiving (via award) 4,000 shares valued at $0.
Sue Gail Eckhardt currently holds 16,000 shares of Syros Pharmaceuticals, Inc. (SYRS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sue Gail Eckhardt has been a net neutral trader of SYRS stock. They have purchased $0 and sold $0 worth of shares.
Sue Gail Eckhardt's most recent insider trade was on Jun 5, 2024, when they sold 4,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jan 5, 2024 | EXEL | $0 | Award | 15,424 | $N/A | Discretionary |
| Jun 1, 2023 | SYRS | $0 | Award | 4,000 | $N/A | Discretionary |
| Sep 16, 2022 | SYRS | $0 | Award | 8,000 | $N/A | Discretionary |